Table 1. Study groups and demographics.
| Study groups | No | % | Age* (years) | BMI* kg/m2 |
|---|---|---|---|---|
| Proliferative phase | 16 | 39 (30–49) | 26.7 (18–46) | |
| Postmenopausal | 15 | 64 (52–79) | 26 (22–38) | |
| Endometrial hyperplasia with atypia | 11 | 55 (48–73) | 30.10 (24–57) | |
| Endometrial cancer | 100 | 67 (41–89) | 30.7 (20–54) | |
| LGEC | 50 | 50 | 64 (41–84) | 30.8 (22–54) |
| Grade1 | 30 | 30 | 64 (51–84) | 32 (22–53) |
| Grade2 | 20 | 20 | 64 (41–77) | 29 (22–54) |
| HGEC | 50 | 50 | 70 (51–89) | 29.6 (20–43) |
| Grade3 | 15 | 17 | 69 (51–83) | 26.7 (22–43) |
| Serous | 8 | 8 | 73 (64–82) | 29.8 (25–35) |
| Clear cell | 12 | 12 | 69 (52–82) | 29.9 (25–32) |
| Carcinosarcoma | 15 | 15 | 78 (59–89) | 24.2 (20–37) |
| Metastatic lesions | 16 | 68 (41–89) | – |
*Data expressed as median (range).